247 related articles for article (PubMed ID: 29705792)
1. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
Moehler M; Göpfert K; Lenz HJ
Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Gastrointestinal Carcinoma - How to Separate Hope from Hype.
Moehler M
Oncol Res Treat; 2018; 41(5):264-265. PubMed ID: 29705785
[No Abstract] [Full Text] [Related]
3. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
Alsina M; Moehler M; Lorenzen S
Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
[TBL] [Abstract][Full Text] [Related]
4. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
Sebio A; Wilky BA; Keedy VL; Jones RL
Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of Hepatocellular Carcinoma.
Heinrich B; Czauderna C; Marquardt JU
Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
8. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies.
Zhang Y; Xu J; Zhang N; Chen M; Wang H; Zhu D
Cancer Lett; 2019 Aug; 458():123-135. PubMed ID: 31121212
[TBL] [Abstract][Full Text] [Related]
9. Development of adaptive immune effector therapies in solid tumors.
Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P;
Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
[TBL] [Abstract][Full Text] [Related]
11. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors.
Fan J; Zhu J; Zhu H; Xu H
Crit Rev Oncol Hematol; 2024 Jun; 198():104362. PubMed ID: 38614267
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance and new therapies in colorectal cancer.
Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
Bair SM; Mato A; Svoboda J
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
[TBL] [Abstract][Full Text] [Related]
17. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
Cheung PF; Lutz M; Siveke JT
Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
[TBL] [Abstract][Full Text] [Related]
19. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
Flaig TW
J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
